Medicinal Cannabis Industry Approach
The medicinal cannabis industry currently consists of either medical marijuana producers or the traditional pharmaceutical approach. The pharmaceutical approach traditionally involves the study of individual cannabinoids as target molecules for drug discovery. This approach has generally proven to be both costly and time consuming. The rapidly growing medical marijuana industry on the other hand commonly develops inconsistent products, as pharmaceutical grade quality assurance/quality control (QA/QC) is not present. Additionally, these products lack solid scientific proof of effectiveness.
Veritas’ innovative research and development approach aims to solve the critical need for real science to support claims surrounding medical marijuana. Our scientific approach combined with our strategic alliances, will effectively address the concerns over the medical industry’s varied output in content, quality, potency and efficacy.
Veritas Research and development goals are as follows:
- To chemically profile different cannabis cultivars.
- To pharmacologically profile those cultivars in the search for disease specific strains.
- On the basis of the findings above, perform clinical trials to prove clinical utility.
- NOT follow the traditional pharmaceutical development pathway to get to market (i.e., 10+ years).
- Conduct basic safety and efficacy profiling of cultivars.
- Be in clinical trials within 2 years of finding lead cultivar(s).
- Immediately market clinically effective cultivars as prescription medicines.
Veritas’ IP Strategy
Ensure intellectual and market protection:
- Protect cultivars and their use as fully as possible.
- Plant and other protection for cultivars and their unique cannabinoid profiles.
- Specific use of that cultivar for specific therapeutic indications.
- Examples of plant cultivar protection include:
- Plant Breeders’ Rights Act in Canada*
- Patent Act protection for fully described and validated new uses of specific cultivars for specific medical conditions especially for those that have previously been recognized as being effective, or with a new strain of cannabis obtained by genetic engineering**
- Expanding this to world wide patents
Current Research Status
- Established the necessary laboratory space and equipment for the regulated chemical and pharmacologic analysis.
- Established a variety of animal models of disease conditions including pain, nausea, behavioural, safety (cardiac and respiratory) with complementary screening procedures in isolated cell cultures.
- In terms of chemistry, over 250 experiments have been performed thus far while pharmacological and biological studies number over 150.
- Two cannabis strains have been identified as potentially therapeutic; one for pain and the other for nausea.
- In conclusion, we have a skilled and trained team of scientists that have been able to realise more of the therapeutic potential of cannabis in a comprehensively scientific and systematic manner.
Next Research Steps
- Results to date have allowed Veritas to focus on performing clinical trials in order to establish the efficacy of candidate strains specifically in terms of their effects on humans and treatment of human diseases.
- Preparation of scientific literature (conference abstracts, peer-reviewed journal articles, book publications, etc.) for the education of the medical community and to establish Veritas’ reputation and brand.
Veritas Research Timetable
- Continue obtaining varied marijuana cultivars from various licensed producers and move them through the research process.
- Continue to assess patent landscape.
- Prepare patent applications based on results (pain).
- Determine potential cultivars for clinical testing.
Target Disease Conditions
Clinical trials will focus on demonstrating the clinical utility of the following disease conditions:
- Chronic Pain (e.g. cancer pain)
- Nausea & Vomiting
- Muscle Spasms
- Post-Traumatic Stress Disorder (PTSD)